Clinical Trials

56 enrolled

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma

NCT04134325 2026-04-17

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Disease

NCT05119296 2026-04-17

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

12 enrolled

Thyroid Neoplasms

NCT07523763 2026-04-17

NIVO1002024

30 enrolled

Colorectal Neoplasms

NCT03435952 2026-04-16

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

18 enrolled

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

35 enrolled

Meningioma

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

25 enrolled

Phase 1/2 Active not recruiting

Hodgkin Disease

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

20 enrolled 11 charts

Carcinoma, Oropharyngeal Neoplasms

NCT04520711 2026-04-13

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Phase 1/2 Active not recruiting

24 enrolled

Tumor-Agnostic

Carcinoma

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

32 enrolled

Brain Neoplasms, Glioblastoma

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT04938609 2026-04-09

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled 9 charts

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

46 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03240211 2026-04-07

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoma, T-Cell

NCT04417166 2026-04-07

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

30 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01822652 2026-04-06

GRAIN

11 enrolled

Neuroblastoma, Recurrence

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

39 enrolled 7 charts

Endocrine

Adrenocortical Carcinoma

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06514898 2026-04-03

MATCHPOINT

12 enrolled

Medulloblastoma

NCT06236425 2026-04-01

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

7 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06242834 2026-04-01

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

32 enrolled

Lymphoma, B-Cell

NCT05980000 2026-03-31

Rambro2

37 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

51 enrolled

Breast

Breast Neoplasms

NCT06178445 2026-03-27

TRAP-BTC

24 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

52 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03361852 2026-03-25

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT04074096 2026-03-25

BEPCOME-MB

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Dermatologic

Melanoma

NCT03463460 2026-03-23

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

9 enrolled

Thoracic

Thymoma

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Dermatologic

Skin Neoplasms

NCT04960618 2026-03-23

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

14 enrolled

Mycosis Fungoides, Sezary Syndrome

NCT02852655 2026-03-20

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

60 enrolled 19 charts

Phase 3 Active not recruiting

Brain Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Genitourinary

Carcinoma, Transitional Cell

NCT04430699 2026-03-19

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

24 enrolled

Gynecologic

Vulvar Neoplasms

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

36 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Other solid neoplasmThoracic

7 enrolled

Mesothelioma, Malignant

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

136 enrolled

Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT02959463 2026-03-06

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Other solid neoplasmThoracic

24 enrolled 11 charts

Mesothelioma, Malignant

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Phase EARLY_PHASE1 Active not recruiting

17 enrolled

Pathologic Complete Response

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Phase NA Active not recruiting

16 enrolled

Gynecologic

Ovarian Neoplasms

NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

27 enrolled